Leishmaniasis during the increased Syrian refugee traffic

Especially in recent years, important population mobility occurs worldwide, including refugee crisis affecting especially Middle East and Europe. Consequently, like other infectious diseases have signifi cance for public health, leishmaniasis is spreading globally. 350 million people in 88 countries, mostly in developing areas, are at risk of leishmaniasis. The diseases may be seen in three clinical forms as cutaneous, mucocutaneous, or visceral caused by about 20 different species of Leishmania parasite. The parasitological diagnosis is made by microscopic examination, cultivation, PCR and serological methods. There is currently no available vaccine for this infection. Pentavalent antimonials are the fi rst line therapeutic choice, whereas amphotericin B, pentamidine, miltefosine, and paromomycin are alternative drugs. Other side, increasing resistance and toxicity of the current therapeutics are signifi cant problems. The combination therapy, immunotherapy, anti-leishmanial synthetic and natural products, and local hyperthermic applications are promising for future treatment of leishmaniasis. The preventive efforts have been applying based on individuals and community.In CHB patients, habits of drinking alcohol and cigarette smoking, elevated serum levels of TBil and serum AST/ALT ratio, increased duration of hepatitis B, a family of hepatitis B, male gender and older age can increase the risk of LC development. Review Article Leishmaniasis during the increased Syrian refugee traffi c Nurittin Ardic1*, Alper Fatih Ardic2 and Zeynep Gunel3 1Intergen Genetic Diseases Diagnosis and Research Center, Ankara, Turkey 2Gazi University, School of Medicine, Ankara, Turkey 3Koc University, School of Medicine, Istanbul, Turkey Received: 05 December, 2018 Accepted: 18 December, 2018 Published: 19 December, 2018 *Corresponding authors: Nurittin Ardic, Intergen Genetic Diseases Diagnosis and Research Center, Mustafa Kemal Mahallesi 2119. Sok. No:5 06510 Cankaya/Ankara, Turkey, E-mail:


Introduction
In last several years, an important population relocation occurs worldwide for various reasons, including immigrants, refugees, and international students [1,2]. In the US National Intelligence Council study (2000), it is reported that nearly two million people each day travel across borders, and it is estimated that 2% of the world's population resides in a nation different than the one in which they were born [3]. This movement of people led to the spread of global infectious disease [4].
During the on-going confl ict in Syria, which is one of the southern border neighbor of Turkey, about 6.5 million people are displaced within the country, as well as more than 4.2 million Syrians have crossed borders. Turkey hosts more than 2.7 million, Lebanon 1 million, Jordan 630,000 and Iraq 235,000 refugees, and approximately 682,000 asylum applications happened to Europe countries [5][6][7]. Cutaneous leishmaniasis (CL) is highly endemic in Syria. In addition to some other infectious diseases, the number of leishmaniasis, especially cutaneous form, cases increased in Turkey and the other countries depend on crowded and bad environments. The increased mobility due to the confl ict can be considered an emerging new threat for unaffected regions [6]. Since these kinds of risk factors led to an increase in the variability of species and a rise in the frequency of infectious agents, it is required to reevaluate the treatment policy [8,9]. We focused on leishmaniasis rather than other diseases because CL is a major health problem in Turkey. Therefore, we aimed to summarize the current knowledge on leishmaniasis in this review.  [10]. The visceral form could be fatal, while the skin lesions in cutaneous form tend to heal spontaneously, or scarifi cation affecting life quality [11,12].
Leishmaniasis is an increasing major public health problem in Turkey, as well worldwide. The population movement has a considerable role in spread of infectious diseases, including leishmaniasis This may require reevaluating the treatment and prevention measurements policy of the disease.

Epidemiology and etiology
The leishmaniasis is widely seen across the tropical, Upon the sand-fl y injecting the promastigote form (1.5 to 3.5 by 15 to 200 μm) into the skin of the host, the parasites are taken up by macrophages. Then the promastigote forms differentiate into amastigote forms (3 to 5 μm in length) ( Figure 1). Interestingly, the parasites replicate in the immune defense cells following the differentiation [13].

Immunologic response in leishmaniasis
The host immunological response varies widely between species; especially Th1-type immune response has a crucial role in the infection control [13]. Parasitic clearance is happened by nitric oxide (NO) which is produced by macrophages. Some cytokines such as IFN- and TNF- activate macrophages to produce nitric oxide, while cytokines like IL-4, IL-10, IL-13, and TGF- dampen NO production, thereby decreasing the leishmanicidal ability of the cells [19,20]. Besides being an important effector cell, macrophage have a role in antigenpresenting to T cells [21]. On the other hand, macrophage can serve as a host for the replication and spread of the parasite by in inhibition of phagosome-endosome fusion, thereafter referring as Trojan horse [22]. In condition aparasite-driven Th2 response, it is seen a progression of the disease mediated by the expression of non-protectiveTh2-related cytokines such as IL-4, IL-10 and IL-13 [20]. Like this, Th1 suppressing cytokines such as TGF- and IL-10 increase susceptibility to VL [23].

Clinical Manifestations of Leishmaniasis Visceral leishmaniasis
Visceral form of the illness is a systemic infection, which affecting the liver, spleen, and bone marrow. The spectrum of VL varies from asymptomatic to life-threatening degree in severity. VL is caused by both New and Old World species [24,25].The incubation period ranges from as short as 10 days or longer than a year(usually 3-6 months)depending on the species of Leishmania, as well as the host's immune status, age and the other factors [13].
The disease is known as kala-azar due to the characteristic darkening of the skin. The most common sign and symptoms are hepatosplenomegaly, hypergammaglobulinemia, pancytopenia, fever, and weight loss. The untreated VL may result in death frequently within two years because of hemorrhage, serious anemia, immunosuppression, and secondary infections. Sometimes, multiple, hypopigmented, erythematous macular lesions occur in skin following VL therapy. This is called as post-kala-azar dermal leishmaniasis (PKDL) [20].Lesions in PKDL may resemble leprosy clinically and pathologically [13].

Cutaneous leishmaniasis (CL)
Depending on species of the parasite and host factors, CL represents a broad spectrum in clinical manifestation. The hallmark for CL is skin lesions. The lesions are usually painless and can spontaneously heal in 2-10 months [23]. The incubation period of CL typically ranges from 2 weeks to several months, and sometime years. There is no evident systemic symptom. A species-specifi c immunity occurs following recovery or successful treatment of CL. Generally, L. tropica tends to cause "dry," crusted, slowly enlarging lesions, while the lesions in L. major and L. braziliensis infections tend to be "moist," exudative lesions and larger (Figure 2) [13].
The classic form of Old World CL is also known as "oriental sore" by a variety of colorful local expressions. The clinical spectrum in CL may vary from single or multiple, localized,

Leishmaniasis recidivans (LR) is an infrequent syndrome
that may be seen years after resolution of a localized cutaneous lesion caused by L. tropica [24]. LR lesion is generally seen on the face. LR may infer from reactivation of dormant parasites or new infection with a different species [24,25]. LR has been demonstrated in North Africa, the Middle East, Southwest Asia, as well as Turkey and Iran [13].

Mucocutaneous leishmaniasis (ML)
Mucocutaneous form of the disease, which has a signifi cant rate of morbidity and mortality, is rarely seen in the Old World [26]. ML is mainly a problem of the New World. ML occurs in 2% to 5% of persons infected with L. braziliensis, and more rarely in persons infected with L. panamensis, L. guyanensis, or L.
amazonensis [13]. ML is characterized by mucosal destruction and also known as "espundia" in South America. It usually develops by metastasis from disseminated protozoa rather than by local spread [23]. In ML, mucous membrane involvements usually occur in the nose, oral cavity, pharynx, or larynx months to years after their skin lesions recovered (Table 1) [13].

Diagnosis
The parasitological diagnosis of leishmaniasis is made by microscopic examination, cultivation, PCR and serological methods. The samples obtained by biopsy, scrapings, and/or needle aspirates in the CL, or the specimens from peripheral blood, bone marrow, liver, or splenic aspirates in the VL are examined for parasitological investigation. The smears stained by Leishman, Giemsa, or Wright stains are examined under oil immersion microscope [24]. Specimens are inoculated into one of several media (Schneider's modifi ed media, Novy-

Treatment
Currently, there is no available vaccine for the prevention leishmaniasis. Furthermore, the variability in species of the parasite affects standard treatment recommendations negatively [13]. The fi rst line therapeutic choice is pentavalent antimonials, sodium stibogluconate (SSG) and methylglucamine antimoniate (MA), for all forms of leishmaniasis around the world. The drugs are given intramuscularly (IM), intravenously (IV), or intralesional (IL). Recommended IM and IV regimen is 15-20 mg SbV/kg of body weight daily for 21-28 days [27]. Painful injection, high toxicity and resistance problems are signifi cant disadvantages of the drugs [28,29].
Amphotericin B with different formulations, pentamidine, miltefosine,and paromomycin with intramuscular and topical formulations are commonly used as alternative drugs in the treatment of leishmaniasis [28,29].

Prevention
The preventive approaches to leishmaniasis are handled based on individuals and community. Unfortunately, there is no individual immunoprophylactic prevention (vaccine or immunoglobulin) method for travelers to endemic areas. Standard personal protective measures are recommended applying permethrin or other insecticides to clothing and insecticide-impregnated fi ne-mesh bed nets. In endemic areas, due to zoonotic features of the disease, the vector control and reservoir control applications are effective for communitybased preventive efforts. Residual insecticides can be applied in houses and other buildings. The early diagnosis and complete treatment, integrated vector management and effective vector and disease surveillance establish basis of elimination of the infection [13].

Conclusion
Although leishmaniasis is an old disease, it remains as a signifi cant public health. The disease is spreading and globalizing due to the heavy population movement. To prevent and treat the disease effectively, an important task awaits the scientists of the future, including us.